Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7381724 (Pediatric)	WOODWARD	Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same	Jul, 2012 (11 years ago)
US6319926 (Pediatric)	WOODWARD	Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it	Jul, 2012 (11 years ago)
US6864257	WOODWARD	Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it	Aug, 2012 (11 years ago)
US6864257 (Pediatric)	WOODWARD	Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it	Mar, 2013 (11 years ago)
US6444673	WOODWARD	Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it	Feb, 2014 (10 years ago)
US6444673 (Pediatric)	WOODWARD	Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it	Aug, 2014 (9 years ago)

Lunesta is owned by Woodward.

Lunesta contains Eszopiclone.

Lunesta has a total of 6 drug patents out of which 6 drug patents have expired.

Expired drug patents of Lunesta are:

Lunesta was authorised for market use on 15 December, 2004.

Lunesta is available in tablet;oral dosage forms.

Lunesta can be used as method of inducing a hypnotic or sedative effect in a human by administering eszopiclone.

The generics of Lunesta are possible to be released after 10 April, 2016.

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Apr 10, 2016
M(M-61)	Oct 10, 2015

Market Authorisation Date: 15 December, 2004

Treatment: Method of inducing a hypnotic or sedative effect in a human by administering eszopiclone

Dosage: TABLET;ORAL

Lunesta patents expiration